Two of Ascentage Pharma’s drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.  

Lisaftoclax (APG-2575), an investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. 

This makes lisaftoclax the only China-developed Bcl-2 inhibitor recommended in the CSCO Guidelines. 

Professor Jun Ma, from Harbin Institute of Hematology and Oncology, stated: “These CSCO Guidelines recommendations for lisaftoclax (APG-2575) indicate recognition of the drug’s robust data by a top medical association in China. In the data, lisaftoclax (APG-2575) monotherapy showed a high overall response rate and a fast onset of action that can enable rapid disease control. Moreover, the incidence of tumour-lysis syndrome in patients treated with lisaftoclax (APG-2575) was far lower than was shown in the early data of other Bcl-2 inhibitors, highlighting a favourable tolerability profile that could potentially change the clinical risk management in CLL/SLL.” 

Olverembatinib, a tyrosine kinase inhibitor (TKI), received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, and retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies. 

Professor Xiaofan Zhu, from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, noted: “As a China-developed third-generation TKI, olverembatinib has achieved a major breakthrough in the treatment of children with Ph+ ALL. In the CSCO 2025 Guidelines, the recommendation for olverembatinib in the treatment of patients with Ph+ ALL who harbour the T315I BCR-ABL1 kinase domain mutation or are intolerant to dasatinib has been upgraded to Level I, an update that reflects the drug’s promising clinical utility.”

Diana Spencer, Senior Digital Content Editor, DDW